Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. - Ward LM; Högler W; Glorieux FH; Portale AA; Whyte MP; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Sochett E; et al. (JBMR plus, 2024)